Breaking Finance News

A statement released earlier today by Raymond James about Spark Therapeutics (NASDAQ:ONCE) bumps the target price to $96.00

Boasting a price of $86.20, Spark Therapeutics (NASDAQ:ONCE) traded 0.00% even on the day. With the last close up 0.34% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Spark Therapeutics has recorded a 50-day average of $85.91 and a two hundred day average of $85.91. Volume of trade was up over the average, with 536,939 shares of ONCE changing hands over the typical 447,313

Raymond James bumped up the target of Spark Therapeutics (NASDAQ:ONCE) to $96.00 stating a potential upside of 0.11%.

On 9/15/2017, RBC Capital released a statement on Spark Therapeutics (NASDAQ:ONCE) bumped up the target price from $0.00 to $100.00 that suggested an upside of 0.23%.

Performance Chart

Spark Therapeutics (NASDAQ:ONCE)

With a total market value of $0, Spark Therapeutics has with a one year low of $35.07 and a one year high of $91.00 .

A total of 9 analysts have released a research note on ONCE. zero analysts rating the company a strong buy, five analysts rating the company a buy, three analysts rating the company a hold, zero analysts rating the company a underperform, and finally one analyst rating the company a sell with a one year target of $58.44.

More About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.